Phương Pháp Mới Về Nội Đoái Vô Sinh - Vô Trùng (IVIVE) Để Dự Đoán Thải Chất Gan Ở Chuột

Müller M, Jansen PL. Molecular aspects of hepatobiliary transport. Am J Physiol. 1997;272(6 Pt 1):G1285–303. Lee JK, Marion TL, Abe K, Lim C, Pollock GM, Brouwer KL. Hepatobiliary disposition of troglitazone and metabolites in rat and human sandwich-cultured hepatocytes: use of Monte Carlo simulations to assess the impact of changes in biliary excretion on troglitazone sulfate accumulation. J Pharmacol Exp Ther. 2010;332(1):26–34. Treijtel N, van Eijkeren JC, Nijmeijer S, de Greef-van der Sandt IC, Freidig AP. Clearance and clearance inhibition of the HIV-1 protease inhibitors ritonavir and saquinavir in sandwich-cultured rat hepatocytes and rat microsomes. Toxicol In Vitro. 2009;23(1):185–93. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther. 1997;73(2):147–71. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 1999;27(11):1350–9. Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, et al. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos. 2010;38(2):215–22. Yamazaki M, Suzuki H, Sugiyama Y. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res. 1996;13(4):497–513. Kusuhara H, Sugiyama Y. Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters. Drug Metab Rev. 2010;42(3):539–50. Kusuhara H, Sugiyama Y. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet. 2009;24(1):37–52. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11–23. Hassen AM, Lam D, Chiba M, Tan E, Geng W, Pang KS. Uptake of sulfate conjugates by isolated rat hepatocytes. Drug Metab Dispos. 1996;24(7):792–8. Eadie GS. The inhibition of cholinesterase by physostigmine and prostigmine. J Biol Chem. 1942;146:85–93. Swift B, Pfeifer ND, Brouwer KL. Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev. 2010;42(3):446–71. Lee PS, Song IS, Shin TH, Chung SJ, Shim CK, Song S, et al. Kinetic analysis about the bidirectional transport of 1-anilino-8-naphthalene sulfonate (ANS) by isolated rat hepatocytes. Arch Pharm Res. 2003;26(4):338–43. Tsuji A, Yoshikawa T, Nishide K, Minami H, Kimura M, Nakashima E, et al. Physiologically based pharmacokinetic model for beta-lactam antibiotics I: tissue distribution and elimination in rats. J Pharm Sci. 1983;72(11):1239–52. Yabe Y, Galetin A, Houston JB. Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab Dispos. 2011;39(10):1808–14. Carlile DJ, Zomorodi K, Houston JB. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. Drug Metab Dispos. 1997;25(8):903–11. Pollack GM, Brouwer KL, Demby KB, Jones JA. Determination of hepatic blood flow in the rat using sequential infusions of indocyanine green or galactose. Drug Metab Dispos. 1990;18(2):197–202. Li X, Zeng S. Stereoselective propranolol metabolism in two drug induced rat hepatic microsomes. World J Gastroenterol. 2000;6(1):74–8. Adachi Y, Suzuki H, Sugiyama Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001;18(12):1660–8. Fan Y, Rodriguez-Proteau R. Ketoconazole and the modulation of multidrug resistance-mediated transport in Caco-2 and MDCKII-MDR1 drug transport models. Xenobiotica. 2008;38(2):107–29. Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. 2008;48(11):1323–38. Yamazaki M, Akiyama S, Niinuma K, Nishigaki R, Sugiyama Y. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos. 1997;25(10):1123–9. Hasegawa M, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. J Am Soc Nephrol. 2007;18(1):37–45. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18(4):377–90. Jørgensen L, Van Beek J, Lund S, Schousboe A, Badolo L. Evidence of Oatp and Mdr1 in cryopreserved rat hepatocytes. Eur J Pharm Sci. 2007;30(2):181–9. Luttringer O, Theil FP, Lavé T, Wernli-Kuratli K, Guentert TW, de Saizieu A. Influence of isolation procedure, extracellular matrix and dexamethasone on the regulation of membrane transporters gene expression in rat hepatocytes. Biochem Pharmacol. 2002;64(11):1637–50. Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, et al. Function of uptake transporters for taurocholate and estradiol 17beta-D-glucuronide in cryopreserved human hepatocytes. Drug Metab Pharmacokinet. 2003;18(1):33–41. Bow DA, Perry JL, Miller DS, Pritchard JB, Brouwer KL. Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes. Drug Metab Dispos. 2008;36(1):198–202. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693–705. Soars MG, Grime K, Sproston JL, Webborn PJ, Riley RJ. Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos. 2007;35(6):859–65. Mano Y, Usui T, Kamimura H. Comparison of inhibition potentials of drugs against zidovudine glucuronidation in rat hepatocytes and liver microsomes. Drug Metab Dispos. 2007;35(4):602–6. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 2009;328(2):652–62. Webborn PJ, Parker AJ, Denton RL, Riley RJ. In vitro-in vivo extrapolation of hepatic clearance involving active uptake: theoretical and experimental aspects. Xenobiotica. 2007;37(10–11):1090–109. Kotani N, Maeda K, Watanabe T, Hiramatsu M, Gong LK, Bi YA, Takezawa T, Kusuhara H, Sugiyama Y. Culture period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes. Drug Metab Dispos. 2011;39(9):1503–10. Li N, Singh P, Mandrell KM, Lai Y. Improved extrapolation of hepatobiliary clearance from in vitro sandwich cultured rat hepatocytes through absolute quantification of hepatobiliary transporters. Mol Pharm. 2010;7(3):630–41. Kilford PJ, Gertz M, Houston JB, Galetin A. Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab Dispos. 2008;36(7):1194–7. Sasaki M, Suzuki H, Aoki J, Ito K, Meier PJ, Sugiyama Y. Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol Pharmacol. 2004;66(3):450–9. Rane A, Wilkinson GR, Shand DG. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther. 1977;200(2):420–4. Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev. 1987;39(1):1–47. Olinga P, Hof IH, Merema MT, Smit M, de Jager MH, Swart PJ, et al. The applicability of rat and human liver slices to the study of mechanisms of hepatic drug uptake. J Pharmacol Toxicol Methods. 2001;45(1):55–63. Sohlenius-Sternbeck AK, Afzelius L, Prusis P, Neelissen J, Hoogstraate J, Johansson J, et al. Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. Xenobiotica. 2010;40(9):637–49. Sathirakul K, Suzuki H, Yasuda K, Hanano M, Sugiyama Y. Construction of a physiologically based pharmacokinetic model to describe the hepatobiliary excretion process of ligands: quantitative estimation of intracellular diffusion. Biol Pharm Bull. 1993;16(3):273–9. Letendre L, Scott M, Dobson G, Hidalgo I, Aungst B. Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. Pharm Res. 2004;21(8):1457–62. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, et al. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos. 2006;34(9):1443–7. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci. 2002;91(1):129–56. Tomcíková O, Bezek S, Durisová M, Faberová V, Zemánek M, Trnovec T. Biliary excretion and enterohepatic circulation of two beta-adrenergic blocking drugs, exaprolol and propranolol, in rats. Biopharm Drug Dispos. 1984;5(2):153–62. Sugihara N, Furuno K, Kita N, Murakami T, Yata N. Distribution of quinidine in rats with carbon tetrachloride-intoxicated hepatic disease. J Pharmacobiodyn. 1992;15(4):167–74. Watari N, Wakamatsu A, Kaneniwa N. Comparison of disposition parameters of quinidine and quinine in the rat. J Pharmacobiodyn. 1989;12(10):608–15. Bhatti MM, Foster RT. Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model. Biopharm Drug Dispos. 1997;18(5):387–96. Yamano K, Yamamoto K, Kotaki H, Takedomi S, Matsuo H, Sawada Y, et al. Correlation between in vivo and in vitro hepatic uptake of metabolic inhibitors of cytochrome P-450 in rats. Drug Metab Dispos. 1999;27(11):1225–31. Ling S, Jamali F. The effect of infliximab on hepatic cytochrome P450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: a drug-disease and drug-drug interaction. Basic Clin Pharmacol Toxicol. 2009;105(1):24–9. Kawai R, Mathew D, Tanaka C, Rowland M. Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. J Pharmacol Exp Ther. 1998;287(2):457–68. Tanaka C, Kawai R, Rowland M. Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues. Drug Metab Dispos. 2000;28(5):582–9. Wagner O, Schreier E, Heitz F, Maurer G. Tissue distribution, disposition, and metabolism of cyclosporine in rats. Drug Metab Dispos. 1987;15(3):377–83. Remmel RP, Amoh K, Abdel-Monem MM. The disposition and pharmacokinetics of ketoconazole in the rat. Drug Metab Dispos. 1987;15(6):735–9. Saadeddin A, Peris JE. Pharmacokinetic interaction between efavirenz and ketoconazole in rats. Xenobiotica. 2009;39(2):135–9. Black AE, Hayes RN, Roth BD, Woo P, Woolf TF. Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab Dispos. 1999;27(8):916–23. Lau YY, Okochi H, Huang Y, Benet LZ. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos. 2006;34(7):1175–81. Paine SW, Parker AJ, Gardiner P, Webborn PJ, Riley RJ. Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab Dispos. 2008;36(7):1365–74. Fukuda H, Ohashi R, Tsuda-Tsukimoto M, Tamai I. Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes. Drug Metab Dispos. 2008;36(7):1275–82. Michel G, Bergeron F, John G, Michael B, Louis W, Stanley C. Renal tubular transport of penicillin G and carbenicillin in the rat. J Infect Dis. 1975;132(4):374–83. Harrison LI, Gibaldi M. Pharmacokinetics of digoxin in the rat. Drug Metab Dispos. 1976;4(1):88–93. Peng SX, Ritchie DM, Cousineau M, Danser E, Dewire R, Floden J. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. J Pharm Sci. 2006;95(9):1984–93. Evans RL, Owens SM, Ruch S, Kennedy RH, Seifen E. The effect of age on digoxin pharmacokinetics in Fischer-344 rats. Toxicol Appl Pharmacol. 1990;102(1):61–7. Chen C, Scott D, Hanson E, Franco J, Berryman E, Volberg M, et al. Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats. Pharm Res. 2003;20(1):31–7. Wallin JD, Ryals P, Kaplowitz N. Metabolic clearance of furosemide in the rat. J Pharmacol Exp Ther. 1977;200(1):52–7. Yang KH, Choi YH, Lee U, Lee JH, Lee MG. Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism. J Pharm Pharmacol. 2009;61(1):47–54. Chen Q, Tung EC, Ciccotto SL, Strauss JR, Ortiga R, Ramsay KA, et al. Effect of the anticoagulant ethylenediamine tetra-acetic acid (EDTA) on the estimation of pharmacokinetic parameters: A case study with tigecycline and ciprofloxacin. Xenobiotica. 2008;38(1):76–86. Nouaille-Degorce B, Veau C, Dautrey S, Tod M, Laouari D, Carbon C, et al. Influence of renal failure on ciprofloxacin pharmacokinetics in rats. Antimicrob Agents Chemother. 1998;42(2):289–92. Lombardo F, Obach RS, Shalaeva MY, Gao F. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. J Med Chem. 2004;47(5):1242–50.